SEC Form 4 · accession 0001104659-19-009925
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Srinivas Akkaraju
Director
Period of report
Feb 19, 2019
Accepted (ET)
Feb 21, 2019 · 8:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 19, 2019 | S | 23,438 | $128.78 | D | 210,937 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2018.
- F2Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein.